ERBB2 and breast cancer: The predictive biomarkers in breast cancer are the estrogen (ER), progesterone (PR) receptors and human epidermal growth factor receptor HER2 (erbB2/neu) [2] whose overexpression is associated with a lower probability of response to tamoxifen and trastuzumab [3].